FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124464299> ?p ?o ?g. }

• W2124464299 endingPage "1066" @default.
• W2124464299 startingPage "1059" @default.
• W2124464299 abstract "Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This phase III study assessed the efficacy of vandetanib versus erlotinib in unselected patients with advanced non–small-cell lung cancer (NSCLC) after treatment failure with one to two prior cytotoxic chemotherapy regimens. Patients and Methods One thousand two hundred forty patients were randomly assigned to receive vandetanib 300 mg/d (n = 623) or erlotinib 150 mg/d (n = 617). The primary objective was to show superiority in progression-free survival (PFS) for vandetanib versus erlotinib. If the difference did not reach statistical significance for superiority, a noninferiority analysis was conducted. Results There was no significant improvement in PFS for patients treated with vandetanib versus erlotinib (hazard ratio [HR], 0.98; 95.22% CI, 0.87 to 1.10; P = .721); median PFS was 2.6 months for vandetanib and 2.0 months for erlotinib. There was also no significant difference for the secondary end points of overall survival (HR, 1.01; P = .830), objective response rate (both 12%), and time to deterioration of symptoms for pain (HR, 0.92; P = .289), dyspnea (HR, 1.07; P = .407), and cough (HR, 0.94; P = .455). Both agents showed equivalent PFS and overall survival in a preplanned noninferiority analysis. Adverse events (AEs; any grade) more frequent with vandetanib than erlotinib included diarrhea (50% v 38%, respectively) and hypertension (16% v 2%, respectively); rash was more frequent with erlotinib than vandetanib (38% v 28%, respectively). The overall incidence of grade ≥ 3 AEs was also higher with vandetanib than erlotinib (50% v 40%, respectively). Conclusion In patients with previously treated advanced NSCLC, vandetanib showed antitumor activity but did not demonstrate an efficacy advantage compared with erlotinib. There was a higher incidence of some AEs with vandetanib." @default.
• W2124464299 created "2016-06-24" @default.
• W2124464299 creator A5008578055 @default.
• W2124464299 creator A5008880845 @default.
• W2124464299 creator A5009677422 @default.
• W2124464299 creator A5010727297 @default.
• W2124464299 creator A5013804417 @default.
• W2124464299 creator A5030059045 @default.
• W2124464299 creator A5035278067 @default.
• W2124464299 creator A5042702356 @default.
• W2124464299 creator A5057287090 @default.
• W2124464299 creator A5061515387 @default.
• W2124464299 creator A5073724595 @default.
• W2124464299 creator A5081587983 @default.
• W2124464299 creator A5084295219 @default.
• W2124464299 creator A5085237357 @default.
• W2124464299 creator A5087836238 @default.
• W2124464299 date "2011-03-10" @default.
• W2124464299 modified "2023-10-18" @default.
• W2124464299 title "Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer" @default.
• W2124464299 cites W1839238860 @default.
• W2124464299 cites W1998482951 @default.
• W2124464299 cites W2004350020 @default.
• W2124464299 cites W2020830322 @default.
• W2124464299 cites W2037139573 @default.
• W2124464299 cites W2043103956 @default.
• W2124464299 cites W2062316437 @default.
• W2124464299 cites W2100785570 @default.
• W2124464299 cites W2109567704 @default.
• W2124464299 cites W2109833554 @default.
• W2124464299 cites W2111060860 @default.
• W2124464299 cites W2114940128 @default.
• W2124464299 cites W2120718661 @default.
• W2124464299 cites W2122553809 @default.
• W2124464299 cites W2125212831 @default.
• W2124464299 cites W2130652363 @default.
• W2124464299 cites W2134667653 @default.
• W2124464299 cites W2138297714 @default.
• W2124464299 cites W2145774014 @default.
• W2124464299 cites W2145835533 @default.
• W2124464299 cites W2146404049 @default.
• W2124464299 cites W2167571044 @default.
• W2124464299 cites W2169331014 @default.
• W2124464299 cites W4302377883 @default.
• W2124464299 doi "https://doi.org/10.1200/jco.2010.28.5981" @default.
• W2124464299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21282542" @default.
• W2124464299 hasPublicationYear "2011" @default.
• W2124464299 type Work @default.
• W2124464299 sameAs 2124464299 @default.
• W2124464299 citedByCount "270" @default.
• W2124464299 countsByYear W21244642992012 @default.
• W2124464299 countsByYear W21244642992013 @default.
• W2124464299 countsByYear W21244642992014 @default.
• W2124464299 countsByYear W21244642992015 @default.
• W2124464299 countsByYear W21244642992016 @default.
• W2124464299 countsByYear W21244642992017 @default.
• W2124464299 countsByYear W21244642992018 @default.
• W2124464299 countsByYear W21244642992019 @default.
• W2124464299 countsByYear W21244642992020 @default.
• W2124464299 countsByYear W21244642992021 @default.
• W2124464299 countsByYear W21244642992022 @default.
• W2124464299 countsByYear W21244642992023 @default.
• W2124464299 crossrefType "journal-article" @default.
• W2124464299 hasAuthorship W2124464299A5008578055 @default.
• W2124464299 hasAuthorship W2124464299A5008880845 @default.
• W2124464299 hasAuthorship W2124464299A5009677422 @default.
• W2124464299 hasAuthorship W2124464299A5010727297 @default.
• W2124464299 hasAuthorship W2124464299A5013804417 @default.
• W2124464299 hasAuthorship W2124464299A5030059045 @default.
• W2124464299 hasAuthorship W2124464299A5035278067 @default.
• W2124464299 hasAuthorship W2124464299A5042702356 @default.
• W2124464299 hasAuthorship W2124464299A5057287090 @default.
• W2124464299 hasAuthorship W2124464299A5061515387 @default.
• W2124464299 hasAuthorship W2124464299A5073724595 @default.
• W2124464299 hasAuthorship W2124464299A5081587983 @default.
• W2124464299 hasAuthorship W2124464299A5084295219 @default.
• W2124464299 hasAuthorship W2124464299A5085237357 @default.
• W2124464299 hasAuthorship W2124464299A5087836238 @default.
• W2124464299 hasConcept C121608353 @default.
• W2124464299 hasConcept C126322002 @default.
• W2124464299 hasConcept C143998085 @default.
• W2124464299 hasConcept C197934379 @default.
• W2124464299 hasConcept C2776256026 @default.
• W2124464299 hasConcept C2778019345 @default.
• W2124464299 hasConcept C2778087573 @default.
• W2124464299 hasConcept C2778570526 @default.
• W2124464299 hasConcept C2778695046 @default.
• W2124464299 hasConcept C2779438470 @default.
• W2124464299 hasConcept C2780333294 @default.
• W2124464299 hasConcept C71924100 @default.
• W2124464299 hasConcept C90924648 @default.
• W2124464299 hasConceptScore W2124464299C121608353 @default.
• W2124464299 hasConceptScore W2124464299C126322002 @default.
• W2124464299 hasConceptScore W2124464299C143998085 @default.
• W2124464299 hasConceptScore W2124464299C197934379 @default.
• W2124464299 hasConceptScore W2124464299C2776256026 @default.
• W2124464299 hasConceptScore W2124464299C2778019345 @default.
• W2124464299 hasConceptScore W2124464299C2778087573 @default.

• next